Results 51 to 60 of about 17,658 (223)

Pankreaskarzinom: Langzeitdaten zu nab-Paclitaxel [PDF]

Im Focus Onkologie, 2015
Nab-Paclitaxel konnte in einer grosen Phase-III-Studie das Gesamtuberleben von Patienten mit metastasiertem Pankreaskarzinom verlangern. Nun liegen Langzeitdaten dieser Studie vor.
openaire   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen, Yangyi Wang, Tingting Li, Changqing Guo, Zhe Xie, Zhixian Zhang, Xinghua Han, Wei Wang, Jian Wang, Xiaopeng Ma, Yuanzeng Min   +10 more
wiley   +1 more source

Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuro­pathy: a cross-sectional cohort study

Acta Oncologica
Background and purpose: There remains limited evidence regarding the relative neurotoxic potential of nab-paclitaxel long-term. This cross-sectional matched cohort study aimed to compare the severity and natural history of chemotherapy-induced peripheral
Terry Trinh, Kimberley Au, Arun V. Krishnan, Hannah C. Timmins, Tiffany Li, Peter Grimison, David Goldstein, Susanna B. Park   +7 more
doaj   +1 more source

Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer‐Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy

Advanced Science, EarlyView.
A Transformer‐based AI framework, DLINP, screens millions of compounds to identify Co68, a cobalt‐pincer organometallic complex that biases TLR4‐MD2 signaling toward antitumor interferon activation while suppressing inflammatory toxicity through an early TLR4‐SYK‐STAT1 axis.
Xuefei Guo, Yang Zhao, Xianle Rong, Xingyu Chen, Xiao Wang, Tianyi Liu, Yunfei Xie, Yushu Zou, Pingsen Zhao, Qiang Liu, Fuping You   +10 more
wiley   +1 more source

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel) [PDF]

Frontiers in Oncology, 2014
Platinum-based chemotherapy doublets have been the standard approach to first-line therapy for more than a decade. Many randomized trials testing new combinations have not been able to produce significant gains in patient outcomes when these studies have looked at an unselected patient population. The recognition of the biologic importance of histology
Blais, Normand, Hirsh, Vera
openaire   +3 more sources

Molecular Landscapes of Tumor Dormancy in Gynecologic Malignancies: From Survival Mechanisms to Precision Interception

Advanced Science, EarlyView.
This Review outlines the biological framework of entry, maintenance, and awakening in dormant minimal residual disease across gynecologic cancers. By mapping critical biological dependencies—from metabolic plasticity to microenvironment interactions—it evaluates novel interception concepts and presents a translational framework combining single‐cell ...
Shih‐Hsuan Cheng, Ren‐Wang Peng, Chang‐Cheng Wu, Chi‐Wen Luo, Emmanuel Naveen Raj, Zhi‐Hong Wen, Tzu‐Hung Hsiao, Chia‐Jung Li   +7 more
wiley   +1 more source

Albumin-bound paclitaxel in solid tumors: clinical development and future directions

Drug Design, Development and Therapy, 2015
Madappa N Kundranda,1 Jiaxin Niu21Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, 2Department of Medical Oncology, Cancer Treatment Centers of America, Goodyear, Arizona, USA Abstract: Albumin-bound paclitaxel (nab-paclitaxel) is a solvent ...
Kundranda MN, Niu J
doaj  

Paclitaxel drives TREM2+ macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel

Nature Communications
Paclitaxel and nab-paclitaxel differ in therapeutic efficacy and modulation of the tumor immune microenvironment, yet the molecular basis remains poorly defined.
Yuqi Xing, Ruiqi Zhong, Qianchen Li, Xinwei Duan, Moyang Xu, Miao Yu, Chenying Liu, Junming He, Yi Sun, Yunling Wang, Xiaojing Guo, Yunfei Xu, Hongnan Mo, Fei Ma, Hongquan Zhang, Jun Zhan   +15 more
doaj   +1 more source

Lactate‐H3K18la‐RPL11 Axis Drives Gemcitabine Resistance in Pancreatic Cancer by Integrating Protein Synthesis and DNA Damage Repair

Advanced Science, EarlyView.
A lactate‐H3K18la epigenetic axis upregulates RPL11 to drive gemcitabine resistance in pancreatic cancer. RPL11 orchestrates chemoresistance through a dual, compartmentalized role: enhancing cytoplasmic protein synthesis via EEF1A1 stabilization and promoting nuclear DNA damage repair by co‐activating PARP14, thus ensuring robust cell survival ...
Lijun Zhao, Jianzhong Cao, Wenyue Liu, Xuyun Li, Haolin Zhang, Xiaofang Zhang, Shiyang Shi, Huilong Yin, Junjie Li, Angang Yang, Rui Zhang   +10 more
wiley   +1 more source

NDFIP2 Suppresses Colorectal Cancer Metastasis Through DDX3X‐Dependent R‐Loop Remodeling and GNG13 Transcriptional Activation

Advanced Science, EarlyView.
NDFIP2 recruits NEDD4 to promote K48‐linked ubiquitination and proteasomal degradation of DDX3X, leading to R‐loop accumulation and CTCF‐dependent suppression of GNG13 transcription. Consequently, PI3K/AKT signaling, EMT, stemness, and colorectal cancer metastasis are inhibited.
Enjian Zhang, Yanfang Li, Jiaxin Shu, Shang Xu, Heng Lv, Chong Zhang, Pengbo Zhang, Nai Wu, Shuai Gong, Xiuzhong Zhang, Zeqiang Ren, Yi Zhang, Xin Liu   +12 more
wiley   +1 more source